Abstract: The present disclosure generally relates to methods for sending event notifications. In some examples, a controller periodically sends messages concerning a status of an event corresponding to the controller. In some examples, at a first time while periodically sending the messages and in accordance with a determination that the status of the event has changed, the controller sends a message concerning data other than the status of the event. In some examples, at the first time while periodically sending the messages and in accordance with a determination that the status of the event has not changed, the controller continues to periodically send the messages without sending the message concerning data other than the status of the event.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: This invention relates to C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), vectors encoding the same, and methods of using the same for a male subject that has undergone prostate surgery to treat urological symptoms of the surgery.

Abstract: The present disclosure provides compositions and methods for treatment of a kidney disease with chemokine protein stromal cell-derived factor 1 (SDF-1), such as methods of treating a subject afflicted with or at risk of developing a kidney disease, comprising administering SDF-1 to a kidney of the subject in a treatment-effective amount.

Abstract: The present disclosure provides compositions and methods for treatment of a kidney disease with chemokine protein stromal cell-derived factor 1 (SDF-1), such as methods of treating a subject afflicted with or at risk of developing a kidney disease, comprising administering SDF-1 to a kidney of the subject in a treatment-effective amount.

Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.

Abstract: A foldable shipping container adjustable between an unfolded condition in which said container is suitable for use as a cargo container, and a folded condition for when said container is not being used to store or ship cargo. The foldable shipping container having ways for controlling the rate at which the panels collapse.

Abstract: This invention relates to C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), vectors encoding the same, and methods of using the same for a male subject that has undergone prostate surgery to treat urological symptoms of the surgery.

Abstract: The present disclosure provides compositions and methods for treatment of a kidney disease with chemokine protein stromal cell-derived factor 1 (SDF-1), such as methods of treating a subject afflicted with or at risk of developing a kidney disease, comprising administering SDF-1 to a kidney of the subject in a treatment-effective amount.

Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.

Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.

Abstract: A foldable shipping container adjustable between an unfolded condition in which said container is suitable for use as a cargo container, and a folded condition for when said container is not being used to store or ship cargo. The foldable shipping container having ways for controlling the rate at which the panels collapse.

Abstract: A foldable shipping container adjustable between an unfolded condition in which said container is suitable for use as a cargo container, and a folded condition for when said container is not being used to store or ship cargo. The foldable shipping container comprises a roof panel, a base panel, a door panel, a front panel, a right side panel, and a left side panel where the door panel and front panel are hingedly connected to the roof panel while the right side panel and left side panel are hingedly connected to the base panel.

Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.

Abstract: The present invention discloses a novel apparatus and way for folding a shipping container in order to improve assembly and sealing of the shipping container. A foldable shipping container is provided having an overlapped region where adjacent walls are rotated into position and locked together.

Abstract: A foldable shipping container adjustable between an unfolded condition in which said container is suitable for use as a cargo container, and a folded condition for when said container is not being used to store or ship cargo.

Abstract: A writing instrument comprising a ballpoint pen assembly, a holder for the assembly having two substantially flat surfaces in opposed parallel relation, the thickness of the holder ranging from about 1 to about 4 mm, the ballpoint pen assembly being accommodated in an elongated channel in the holder with a writing tip projecting outwardly therefrom, the flat surfaces having a width at least about ten times the thickness of the holder. The flat surfaces have indicia or the like thereon applied by imprinting one side only of an elongate web, folding thereof to envelop the holder and die-cutting into a desired configuration.